Merck's Keytruda Gets FDA Approval for Rare Cancer Treatment
Merck & Co Inc's Keytruda (pembrolizumab) has recently reached an impressive milestone with its FDA approval. This green light permits its use in combination with pemetrexed and platinum chemotherapy for adult patients battling unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Historic Approval for MPM Treatment
This marks a significant breakthrough, as it is the first occasion that Keytruda has been indicated for treating MPM in the United States. MPM is an aggressive form of cancer that affects the lining of the lungs and chest, posing considerable challenges for both patients and healthcare providers alike.
Highlights from the Trial Data
The FDA's decision was bolstered by pivotal data from the Phase 2/3 IND.227/KEYNOTE-483 trial. Findings showed that combining Keytruda with chemotherapy markedly improves overall survival rates. Specifically, patients receiving this combination saw a 21% reduction in risk of death compared to those treated with chemotherapy alone.
Insights on Overall Survival Rates
In the trial, the median overall survival (OS) for patients treated with Keytruda plus chemotherapy was reported at 17.3 months. In contrast, those who received only chemotherapy had a median OS of 16.1 months. This 1.2-month increase highlights a meaningful enhancement in life expectancy for those with MPM.
Improvements in Progression-Free Survival
Additionally, the treatment plan that included Keytruda displayed significant gains in progression-free survival (PFS) when compared to chemotherapy alone. The overall response rate (ORR) reached 52% for those on the combination therapy, whereas only 29% was reported for chemotherapy alone, showcasing a substantial improvement in treatment effectiveness.
Side Effects and Ongoing Studies
The adverse reactions profile for MPM patients treated with Keytruda aligned with observations from other studies combining Keytruda with pemetrexed and platinum chemotherapy. These results lend confidence regarding the safety of this treatment method.
While this approval marks a notable triumph for Merck and its ongoing cancer research efforts, it’s important to mention that the company recently halted two late-stage studies of Keytruda due to disappointing results.
Discontinued Trials
- The Phase 3 KEYNOTE-867 trial was investigating Keytruda combined with stereotactic body radiotherapy for patients with non-small cell lung cancer stages I or II.
- The Phase 3 KEYNOTE-630 trial focused on the adjuvant treatment of high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation.
Impact on Stock Performance
After the announcement of FDA approval, Merck's stocks saw a slight uptick, trading 0.04% higher at $118.34. This positive reaction reflects investors' belief in Keytruda's potential to make significant advancements in cancer treatment, particularly with this new approval.
Looking Ahead
As Merck continues to uphold its commitment to effective therapies, this approval of Keytruda for malignant pleural mesothelioma offers hope to patients facing this challenging disease. Ongoing research and development in this field could lead to additional treatment options that improve survival rates and enhance the quality of life for those diagnosed with MPM.
Frequently Asked Questions
What is Keytruda used for?
Keytruda is an immune checkpoint inhibitor that treats various cancers, including malignant pleural mesothelioma, typically in combination with chemotherapy.
How does Keytruda work?
Keytruda blocks the PD-1 pathway, empowering the immune system to better recognize and attack cancer cells.
What is malignant pleural mesothelioma?
Malignant pleural mesothelioma is a rare and aggressive cancer that originates in the lining of the lungs and chest, often due to asbestos exposure.
What are the side effects of Keytruda?
Common side effects reported with Keytruda include fatigue, rash, and immune-related reactions, which can generally be managed through medical supervision.
What recent developments have occurred with Merck?
Merck recently received FDA approval for Keytruda in treating MPM and discontinued two late-stage trials due to less-than-expected results.
